These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 17952653)

  • 41. Cannabinoids and neuroprotection.
    Grundy RI; Rabuffetti M; Beltramo M
    Mol Neurobiol; 2001; 24(1-3):29-51. PubMed ID: 11831553
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
    Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
    Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.
    Shoemaker JL; Seely KA; Reed RL; Crow JP; Prather PL
    J Neurochem; 2007 Apr; 101(1):87-98. PubMed ID: 17241118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease.
    Alberch J; Pérez-Navarro E; Canals JM
    Brain Res Bull; 2002 Apr; 57(6):817-22. PubMed ID: 12031278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic potential of cannabinoids in neurodegenerative disorders: a selective review.
    Velayudhan L; Van Diepen E; Marudkar M; Hands O; Suribhatla S; Prettyman R; Murray J; Baillon S; Bhattacharyya S
    Curr Pharm Des; 2014; 20(13):2218-30. PubMed ID: 23829360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroprotective agents: cannabinoids.
    Sánchez AJ; García-Merino A
    Clin Immunol; 2012 Jan; 142(1):57-67. PubMed ID: 21420365
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cannabinoids: mechanisms and therapeutic applications in the CNS.
    Drysdale AJ; Platt B
    Curr Med Chem; 2003 Dec; 10(24):2719-32. PubMed ID: 14529462
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of cannabinoids in neurodegenerative diseases.
    Glass M
    Prog Neuropsychopharmacol Biol Psychiatry; 2001 May; 25(4):743-65. PubMed ID: 11383976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
    Rosenberg EC; Patra PH; Whalley BJ
    Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cannabinoids: between neuroprotection and neurotoxicity.
    Sarne Y; Mechoulam R
    Curr Drug Targets CNS Neurol Disord; 2005 Dec; 4(6):677-84. PubMed ID: 16375685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures.
    Nagayama T; Sinor AD; Simon RP; Chen J; Graham SH; Jin K; Greenberg DA
    J Neurosci; 1999 Apr; 19(8):2987-95. PubMed ID: 10191316
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review.
    Bansal R; Singh R
    Med Res Rev; 2018 Jul; 38(4):1126-1158. PubMed ID: 28697282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The influence of cannabinoids on generic traits of neurodegeneration.
    Fagan SG; Campbell VA
    Br J Pharmacol; 2014 Mar; 171(6):1347-60. PubMed ID: 24172185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Role of Voltage-Gated Calcium Channels in Basal Ganglia Neurodegenerative Disorders.
    Correa BHM; Moreira CR; Hildebrand ME; Vieira LB
    Curr Neuropharmacol; 2023; 21(2):183-201. PubMed ID: 35339179
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Neuroprotective mechanisms of cannabinoids in brain ischemia and neurodegenerative disorders].
    Osuna-Zazuetal MA; Ponce-Gómez JA; Pérez-Neri I
    Invest Clin; 2015 Jun; 56(2):188-200. PubMed ID: 26299059
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
    Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The endocannabinoid system in amyotrophic lateral sclerosis.
    Bilsland LG; Greensmith L
    Curr Pharm Des; 2008; 14(23):2306-16. PubMed ID: 18781981
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cannabinoids and neurodegenerative diseases.
    Romero J; Orgado JM
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):440-50. PubMed ID: 19839933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis.
    Croxford JL; Pryce G; Jackson SJ; Ledent C; Giovannoni G; Pertwee RG; Yamamura T; Baker D
    J Neuroimmunol; 2008 Jan; 193(1-2):120-9. PubMed ID: 18037503
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors.
    Pazos MR; Mohammed N; Lafuente H; Santos M; Martínez-Pinilla E; Moreno E; Valdizan E; Romero J; Pazos A; Franco R; Hillard CJ; Alvarez FJ; Martínez-Orgado J
    Neuropharmacology; 2013 Aug; 71():282-91. PubMed ID: 23587650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.